![Birgit M. Schoeberl](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profil
Birgit M.
Schoeberl worked as a Director at Silver Creek Pharmaceuticals, Inc. and as the Head-Discovery at Merrimack Pharmaceuticals, Inc. She obtained an undergraduate degree from the University of Karlsruhe.
Anciens postes connus de Birgit M. Schoeberl
Sociétés | Poste | Fin |
---|---|---|
MERRIMACK PHARMACEUTICALS, INC. | Corporate Officer/Principal | 24/02/2017 |
Silver Creek Pharmaceuticals, Inc.
![]() Silver Creek Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Silver Creek Pharmaceuticals, Inc. develops novel regenerative medicines. The firm focuses on treating cardiovascular disease. Its molecules are designed to promote resilience and regeneration of damaged tissues after acute or chronic injury. The company was founded in 2010 and is headquartered in San Francisco, CA. | Directeur/Membre du Conseil | - |
Formation de Birgit M. Schoeberl
University of Karlsruhe | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 2 |
---|---|
Merrimack Pharmaceuticals, Inc.
![]() Merrimack Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Its pipeline includes MM-131, MM-141, and MM-310. The company was founded by Anthony J. Sinskey, Gavin MacBeath, and Ulrik B. Nielsen in 1993 and is headquartered in Cambridge, MA. | Health Technology |
Silver Creek Pharmaceuticals, Inc.
![]() Silver Creek Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Silver Creek Pharmaceuticals, Inc. develops novel regenerative medicines. The firm focuses on treating cardiovascular disease. Its molecules are designed to promote resilience and regeneration of damaged tissues after acute or chronic injury. The company was founded in 2010 and is headquartered in San Francisco, CA. | Health Technology |